(RTTNews) - Context Therapeutics Inc. (CNTX) on Thursday said the U.S. Food and Drug Administration has granted Fast Track Designation to its drug candidate CTIM-76 for the treatment of platinum-resistant ovarian cancer in patients who have exhausted standard therapies.
3 views
Context Therapeutics Gains FDA Fast Track Status For CTIM-76 In Ovarian Cancer
(RTTNews) - Context Therapeutics Inc. (CNTX) on Thursday said the U.S. Food and Drug Administration has granted Fast Track Designation to its drug candidate CTIM-76 for the treatment of platinum-resistant ovarian…
